Navigation Links
Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
Date:3/29/2009

In SPIRIT II Trial, XIENCE V Drug Eluting Stent Demonstrates Clinically Meaningful Reductions Compared to TAXUS in Key Safety Endpoints, Including an 88 Percent Reduction in the Risk of Cardiac Death at Three Years

ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Long-term data presented today from Abbott's (NYSE: ABT) SPIRIT II clinical trial demonstrated that the clinical advantages of the XIENCE V(R) Everolimus Eluting Coronary Stent System continued to increase between two and three years compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System / TAXUS(R) Liberte(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS). Both TAXUS Express2 (73 percent of lesions) and TAXUS Liberte (27 percent of lesions) were used as controls in the SPIRIT II trial. The data also showed that patients treated with XIENCE V continue to experience fewer heart attacks, deaths or repeat procedures at the target lesion compared to patients treated with TAXUS out to three years. The results from the SPIRIT II trial were presented during the i2 Summit at the American College of Cardiology's 58th annual scientific session in Orlando, Fla.

Between two and three years, Abbott's market-leading XIENCE V maintained a low cardiac death rate of 0.5 percent, while the observed cardiac death rate for TAXUS more than tripled during the same time period (1.3 percent at two years vs. 4.2 percent at three years)*. Similarly, XIENCE V maintained a low, single-digit rate of major adverse cardiac events (MACE) between two and three years (6.4 percent at two years vs. 6.4 percent at three years), while the observed MACE rate with TAXUS increased approximately 40 percent between two and three years (10.5 percent at two years vs. 14.9 percent at three years)*. MACE is an important composite clin
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
6. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
7. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
8. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
9. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
10. Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows
11. New Study Shows Probiotic Strain Effective in Improving Irritable Bowel Syndrome Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor ... announced the set-up of an optical biopsy program at ... de Grenoble is now the first hospital in ... interventional pulmonology and urology patients an innovative platform for ... to the endomicroscopy technology developed by Mauna Kea Technologies. ...
(Date:3/31/2015)... 30, 2015 Research and Markets ( ... "Global Nuclear Imaging Market 2015-2019" report to their ... Imaging market to grow at a CAGR of 5.89 ... The report, Global Nuclear Imaging market 2015-2019, has been ... from industry experts. The report covers the Americas, and ...
(Date:3/31/2015)... DUBLIN , Mar. 27, 2015 Research and ... addition of the "Intraoperative Imaging Market by Type ... to 2019" report to their offering. ... at a CAGR of 3.5% from 2014 to 2019 ... future due to a number of forces that favor ...
Breaking Medicine Technology:Grenoble University Hospital First Hospital in France to set up a Multidisciplinary Optical Biopsy Program With the Cellvizio Endomicroscopy Platform 2Grenoble University Hospital First Hospital in France to set up a Multidisciplinary Optical Biopsy Program With the Cellvizio Endomicroscopy Platform 3Global Nuclear Imaging Market 2015-2019 with GE healthcare, Philips Healthcare & Siemens Healthcare Dominating 2Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market 2015-2019 2
... DALLAS, January 5, 2012 The " ... Billing & Coding) and Pharmaceutical (Clinical trial & Contract manufacturing) ... " analyzes and studies the major market drivers, restraints, ... and Rest of the world. Browse ...
...  The Musculoskeletal Transplant Foundation (MTF) has announced the release of ... kits. The new sizes--16cm x 20cm and 20cm x 20cm--are ... and their patients. This unique human dermal allograft is specifically ... It has been a year since MTF introduced its bi-lateral ...
Cached Medicine Technology:MarketsandMarkets: Global Healthcare BPO Market worth $330 Billion by 2016 2MarketsandMarkets: Global Healthcare BPO Market worth $330 Billion by 2016 3New, Larger, Bilateral Breast Graft Kits Announced by MTF 2
(Date:4/1/2015)... April 01, 2015 Poisonous plants (poison ... climate change in recent years, increasing significantly in number ... reaction if exposed to poison plants (according to the ... families prepare for summer adventures in nature, they should ... plant reaction is greater than ever. This year, Ivarest ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 On November 24, ... All-Pro Lawrence Taylor to discuss the problem of substance abuse ... his own history of drug abuse and recovery, gives a ... Nicknamed “L.T.” by his teammates on the New York Giants, ... due to failed drug tests, yet he was able to ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 In ... place from April 1-7, the Mesothelioma Applied Research ... new prevention program, to complement its existing work ... , “As part of the Meso Foundation’s mission, ... fears of diseases related to asbestos, including mesothelioma,” ...
(Date:3/31/2015)... Calif. (PRWEB) March 31, 2015 Simeon ... received a nearly $4 million, five-year grant from the ... a team of physicians and scientists from more than ... sites, including Australia, Brazil, Bulgaria, Germany, Hungary, Italy and ... of the bony plates of the skull in infants. ...
(Date:3/31/2015)... 2015 Students, teachers, and the general ... in a drastically different way as current and emerging ... training content is being delivered and received. , Today, ... in an unprecedented way with education becoming individualized, customized ... and CEO, My Mobile University , This is ...
Breaking Medicine News(10 mins):Health News:New Ivarest Poison Ivy Itch Spray Provides All-Day Comfort 2Health News:Lawrence Taylor & Per Wickstrom Discuss the Drug Rehabilitation & Recovery Process 2Health News:Mesothelioma Research Organization Announces New Prevention Program 2Health News:Mesothelioma Research Organization Announces New Prevention Program 3Health News:International team of researchers led by UC Davis receives $4 million NIH grant to study skull disorder in infants 2Health News:International team of researchers led by UC Davis receives $4 million NIH grant to study skull disorder in infants 3Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 2Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 3
... evidence of the damaging impact of marijuana on humans ... symptoms in some people, including hallucinations and paranoid delusions, ... recent study, one compound, cannabidiol, or CBD, made people ... tetrahydrocannabinol, or THC, produced temporary psychotic symptoms in people, ...
... victims of a bite from the Brazilian wandering spider (Phoneutria ... in blood pressure, they also sport an uncomfortable erection. ,And ... Viagras. Scientists say they have figured out the chemical that ... , “The erection is a side effect that everybody who ...
... healthcare scheme proposed by the Australian Federal government. The ... people to opt for private health insurance; yet this plan ... by public hospital, a report has shown. ,Dr ... Research on Health, explained the benefits of doing away with ...
... affect people of all ages. The general public is at ... instruction on ladder use and safety. ,According to ... Journal of Preventive Medicine and conducted by the Center for ... than 2.1 million individuals were treated in U.S. emergency departments ...
... suffer migraine attacks, beware. Recent research has shown the ... depression and suicidal tendencies. They could also be suffering ... ,Teens suffering migraines are prone to depressive tendencies ... such agonizing headaches, a new study has shown. ...
... homes have started coming to the fore. One among fifty ... review by the Department of Ageing, Disability and Home Care, ... involving abuse and lack of care. The main cause was ... carers. ,Advocates nationwide say it is a growing problem ...
Cached Medicine News:Health News:Marijuana can Trigger Psychotic Symptoms, New Study Finds 2Health News:Brazil Spider Offers Hope for Those Suffering from Erectile Dysfunction 2Health News:$3bn Rebate Scheme – Is Australia Making a Prudent Move 2Health News:Ladder-related Injuries on the Rise in U.S 2Health News:Link Between Migraine Attacks in Teens and Suicidal Tendencies 2Health News:Abuse of the Disabled in Government Run Homes 2
... Utilizing technology developed over Guidants 20-year history, ... new foundation for successful treatment outcomes. It ... design with a lower profile shaft,more flexible ... you can cross tight and tortuous anatomy ...
Test for AFP...
... AFP IRMA,is an immunoradiometric assay ... (AFP) in serum. It is,intended ... in either of,two contexts:, (a) ... the,management of patients with,nonseminomatous testicular ...
Abbott offers an array of both in-vitro and molecular diagnostic tests for the detection and monitoring of cancerous conditions in patients....
Medicine Products: